期刊文献+

基于DNA损伤修复的分子靶向治疗:肿瘤靶向治疗的新篇章 被引量:8

Targeting DNA repair pathways: a new episode in targeted cancer therapeutics
下载PDF
导出
摘要 2009年美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)报道一种全新的分子靶向药物可选择性抑制DNA修复相关的关键酶——聚腺苷二磷酸核糖聚合酶-1[poly(ADP-ribose)polymerase-1,PARP-1],对三阴乳腺癌患者有效。这一突破性成果强烈预示以DNA损伤修复通路为靶标的分子治疗可能成为肿瘤治疗的新策略。 DNA,as the fundamental material carrying genetics information,is consistently challenged by endogenous and exogenous stimuli,including oxidative stress,ionizing irradiation,and chemotherapeutic agents,just to name a few. DNA repair mechanisms are then essential for cell survival under stress. Altered DNA repair networks is one of the most important features of cancer cells,which makes targeting DNA repair pathways an emerging strategy in cancer therapeutics. We reviewed the evolving variety of strategies and current potent clinical drug candidates in DNA repair targeting therapeutics.
作者 王东
出处 《第三军医大学学报》 CAS CSCD 北大核心 2014年第22期2243-2248,共6页 Journal of Third Military Medical University
关键词 DNA损伤 DNA修复 肿瘤靶向治疗 DNA damage DNA repair targeted cancer therapy
  • 相关文献

参考文献46

  • 1Ame J C,Rolli V,Schreiber V,et al.PARP-2,A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase[J].J Biol Chem,1999,274(25): 17860-17868.
  • 2Johansson M.A human poly(ADP-ribose) polymerase gene family (ADPRTL): cDNA cloning of two novel poly(ADP-ribose) polymerase homologues[J].Genomics,1999,57(3): 442-445.
  • 3Fong P C,Boss D S,Yap T A,et al.Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers[J].N Engl J Med,2009,361(2): 123-134.
  • 4Gelmon K A,Tischkowitz M,Mackay H,et al.Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2,multicentre,open-label,non-randomised study[J].Lancet Oncol,2011,12(9): 852-861.
  • 5Kaye S B,Lubinski J,Matulonis U,et al.Phase II,open-label,randomized,multicenter study comparing the efficacy and safety of olaparib,a poly (ADP-ribose) polymerase inhibitor,and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer[J].J Clin Oncol,2012,30(4): 372-379.
  • 6BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium[J].Cancer Biol The,2009,8(1): 2-3.
  • 7Gerson S L.MGMT: its role in cancer aetiology and cancer therapeutics[J].Nat Rev Cancer,2004,4(4): 296-307.
  • 8Quinn J A,Jiang S X,Carter J,et al.Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme[J].Clin Cancer Res,2009,15(3): 1064-1068.
  • 9Quinn J A,Jiang S X,Reardon D A,et al.Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent,temozolomide-resistant malignant glioma[J].J Clin Oncol,2009,27(8): 1262-1267.
  • 10Ranson M,Hersey P,Thompson D,et al.Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma[J].J Clin Oncol,2007,25(18): 2540-2545.

同被引文献56

引证文献8

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部